Invitation to presentation of BioArctic’s fourth quarter report for October – December 2025 on February 18 at 9.30 a.m. CET

BioArctic will publish its Q4 2025 report on February 18, 2026 at 08:00 CET and host a presentation at 09:30 CET led by CEO Gunilla Osswald and CFO Anders Martin‑Löf (webcast and teleconference available). As the developer (with Eisai) of Leqembi and holder of antibody programs and BrainTransporter™ technology for neurodegenerative diseases, the company may provide financial results and program updates that could influence investor positioning in Nasdaq Stockholm-listed BIOA B.

Analysis

Market structure: The immediate market mover is BIOA B (Nasdaq Stockholm: BIOA B) and its partner Eisai; a clean Q4 beat or positive operational updates (royalties/milestones from Leqembi) would re-rate BioArctic’s cash-flow visibility and likely lift other small-cap AD developers while pressuring pricing expectations for late-stage competitors (e.g., LLY, RHHBY) by 10–30% on repriced adoption curves. Supply/demand for effective AD therapies remains constrained; stronger uptake signals sustained royalty tail for BioArctic and tighter spreads on small biotech debt in Sweden, while positive surprise would support SEK vs. safe-havens by ~0.5–1% in 1–2 trading days.

Risk assessment: Tail risks include a regulatory/safety reversal (new ARIA or label tightening), partner commercial execution failure at Eisai, or adverse patent/legal rulings — each could drive -30% to -60% moves. Immediate horizon (days): elevated volatility into Feb 18; short-term (weeks/months): sales and reimbursement readouts; long-term (quarters/years): validation of BrainTransporter for licensing revenue. Hidden dependency: BioArctic’s cash flow realization is heavily contingent on Eisai milestones and payer coverage, not direct sales.

Trade implications: Tactical plays should be event-driven and size-conservative: short-dated option structures or small equity positions ahead of Feb 18, scaling up only on confirmed royalty/partnership clarity. Use call spreads or straddles for asymmetric payoff into the webcast, and consider relative-value hedges to isolate company-specific outcomes versus AD-class volatility.

Contrarian angles: Consensus may underweight the optionality of BrainTransporter licensing — a single positive translational readout or partner term could justify a 2–4x re-rating over 12–24 months, while consensus may also be complacent about partner execution risk (Biogen/Aduhelm shows how quickly sentiment reverses). Overreaction risk is real: a marginal beat may be sold; a headline safety/regulatory issue could produce outsized downside beyond fundamentals.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in BioArctic (Nasdaq Stockholm: BIOA B) 1–3 trading days before the Feb 18 Q4 webcast; set a hard stop at -20% and a profit target of +40% within 90 days if royalties/revenue beat consensus by >20% or if Eisai confirms increased uptake.
• Buy a 6–8 week at-the-money call spread on BIOA B sized to 1% portfolio risk (buy ATM, sell a 20–30% OTM call) to capture upside from the Feb 18 presentation while capping premium; close or roll within 10 trading days after the event depending on guidance clarity.
• Implement a pair trade: long 1% BIOA B and short 0.5% Eli Lilly (LLY) to hedge AD-class/regulatory noise while keeping directional exposure to BioArctic’s company-specific newsflow; rebalance if BIOA B moves >25% intraday or if LLY issues a major trial readout.
• Monitor three specific catalysts over the next 60 days: (1) Eisai monthly/quarterly Leqembi sales updates (increase exposure to 3–5% if sequential sales growth >15% MoM), (2) any payer/Medicare coverage developments (add to position if draft guidance is favorable), and (3) safety/regulatory signals (reduce to 0% immediately if FDA/major agency issues a safety alert).